The p73 protein is a tumor suppressor that shares structural and functional similarity with p53. p73 is expressed in two major isoforms; the TA isoform that interacts with p53 pathway, thus acting as tumor suppressor and the N-terminal truncated ΔN isoform that inhibits TAp73 and p53 and thus, acts as an oncogene. By employing a drug repurposing approach, we found that protoporphyrin IX (PpIX), a metabolite of aminolevulinic acid (ALA) applied in photodynamic therapy of cancer, stabilizes TAp73 and activates TAp73-dependent apoptosis in cancer cells lacking p53. The mechanism of TAp73 activation is via disruption of TAp73/MDM2 and TAp73/MDMX interactions and inhibition of TAp73 degradation by ubiquitin ligase Itch.
Introduction
Drug repurposing brings hope for the improved treatment of cancer patients due to the financial toxicity of current cancer care that impacts both, patient care and healthcare system worldwide 1 . p73 and p63 are structural and functional homologs of the p53 tumor suppressor protein. All p53 family proteins share the ability to activate p53 target genes involved in apoptosis and cell cycle control under stress conditions. The TP73 gene structure is complex due to the existence of two alternative promoters (P1 and P2). The P1 promoter drives the expression of transcriptionally active TAp73 isoforms, acting as tumor suppressors, while expression from P2 promoter generates N-terminal truncated ΔNp73 isoforms, acting as dominant negative towards TA isoforms and p53 proteins, and thus known as oncogenes 2 . It has been shown that TA and ΔN isoforms possess distinct, often opposing functions in healthy and cancerous tissues 3 . Next, it has been demonstrated that the outcome of chemotherapy depends on the TA and ΔN isoforms ratio 4 .
Unlike TP53, the gene encoding TP73 is rarely mutated in cancers and the functional isoforms are expressed in the majority of human tumors. TAp73 is found inactivated in cancers by binding to oncogenic ΔNp73, MDM2 and MDMX proteins or by degradation by the ubiquitin ligase Itch 5 6 . Previous studies point at the possibility of exploiting TAp73 as a tumor suppressor for improved cancer therapy. For example it has been demonstrated that p73 via activation of c-Jun N-terminal Kinase (JNK) drives the sensitivity to cisplatin in ovarian cancer cells independent on the p53 status 7 . Next, Nutlin3, a selective inhibitor of MDM2, stabilizes TAp73 and induces TAp73-mediated apoptosis 8 . It has also been demonstrated that simultaneous induction of proteotoxic and oxidative stress leads to JNK-induced phosphorylation of TAp73 and TAp73-mediated cell death in p53-null tumors 9 .
Small molecule protoporphyrin IX (PpIX), is a natural metabolite of δaminolevulinic acid, a pro-drug applied in clinics in photodynamic therapy of cancer (PDT) 10 . PpIX induces HeLa cells' apoptosis per se, without light excitation 11 , stabilizes and activates wild-type p53 in human colon carcinoma cells 12 and binds to p73 13 .
Here, we have found that PpIX activates TAp73 in cancer cells lacking TP53. We demonstrated that PpIX-activated TAp73 compensates for p53 loss in cancer cells and induces apoptosis. The mechanism of transcriptional activation of TAp73 by PpIX is via inhibition of TAp73/MDM2 and TAp73/MDMX interactions. TAp73 protein stabilization is achieved by disrupting TAp73/Itch complex by PpIX.
Results

Protoporphyrin IX inhibits proliferation and induces apoptosis in TP53-null cancer cells
It has been demonstrated that PpIX per se, activates wild-type p53 by disrupting p53/MDM2 complex and induces p53-dependent and independent apoptosis in human colon cancer cells 12 . Since PpIX binds to p73 13 we reasoned that p73 might play role in mediating cell death in p53-null cancer cells upon PpIX treatment. Here, in longterm proliferation assay, we showed that PpIX inhibits growth of several TP53-null cancer cells in a dose-dependent way ( Figure 1a ). Interestingly, overexpression of TAp73α sensitized cancer cells to PpIX as shown in short-and long-term proliferation assays (Figure 1b ,c). Thus accumulated TAp73 contributed to cancer cells' susceptibility to PpIX.
Next, we assessed the genotoxicity of PpIX. The comet assay showed that PpIX did not induce DNA damage in human colon cancer cells (Figure 1d 
Protoporphyrin IX induces TAp73 and its apoptotic target genes in TP53-null cancer cells
To assess the potential of PpIX against other TP53-null human cancer cells than HCT 116 p53-/-, we employed human lung adenocarcinoma cells (H1299) and human osteosarcoma cells (Saos2). The caspase assay showed potent induction of apoptosis by PpIX after 6h in all three cell lines tested (Figure 2a and Supplementary Figure   1a ). Induction of active caspases by PpIX correlated with the accumulation of cleaved PARP-1 in H1299 (Figure 2b ).
TAp73 and p53 recognize the same target genes involved in the apoptotic response.
We found that PpIX at the concentrations from 1 to 5 μg/ml induces accumulation of TAp73 with the concomitant upregulation of its apoptotic targets Noxa and PUMA on both mRNA and protein levels ( Figure 2c 
PpIX-activated TAp73 compensates for p53 loss in inducing apoptosis in TP53-
null cancer cells
To determine if TAp73 is critical for PpIX-induced cancer cells' death, we depleted TAp73 using isoform specific siRNA. PpIX had no effect on the mRNA levels of Since TAp73 protein levels (but not mRNA levels) were upregulated by PpIX in cancer cells (Figure 2d ,e), we performed pulse-chase experiments with cycloheximide (CHX) to assess whether PpIX increases the half-life of TAp73 in cancer cells. We observed that PpIX decreased the TAp73 cellular turnover (Figure 4d ).
The key E3 ubiquitin ligase responsible for TAp73 degradation is Itch 6 . Small molecules inhibiting Itch activity in cancer cells have recently been considered to have anticancer potential 16 . We reasoned that PpIX might inhibit TAp73/Itch interactions to induce TAp73 stabilization. We then co-immunoprecipitated TAp73 and demonstrated that PpIX inhibits TAp73/Itch in both H1299 and HCT TP53-/-cell lines and the inhibition was more pronounced in H1299 cells (Figure 4 e,f).
Taken together, our data showed that PpIX activates TAp73-dependent apoptosis at several levels, namely, by promoting its transcriptional activity and protecting from proteasomal degradation.
Discussion
It has been demonstrated that TAp73 KO mice are prone to carcinogen-induced tumorigenesis and that around 35% of mice cohort develop lung adenocarcinomas 17 .
Acute genetic ablation of ∆N isoforms triggers rapid regression of thymic lymphomas developed in p53-null mice 18 . Thus, deletion of ∆Np63 or ∆Np73 can compensate for p53 tumor suppression in thymic lymphomas, and this occurs due to accumulation of TA isoforms of p63 and p73 and induction of apoptosis 19 . Therefore, accumulated TAp73, similarly to p53, can be considered a promising therapeutic target in tumors deficient or mutant for TP53 gene.
Cancer-related deaths are a major health problem encountered today 20 . Therefore, there is an urgent need for the development of effective oncology drugs for tailored treatment of patients suffering from the metastatic disease. The success of anti-cancer treatment relies on the strategy that allows inhibition of cancer drivers without the induction of apparent side effects. However, such strategies are still at early stage of development.
The p53 reactivation suppresses established tumors in-vivo 21 , yet this strategy is not implemented therapeutically. APR-246/MQ, a compound, in Phase II clinical development (clinical trial ID: NCT03268382), that binds to cysteine residues in mutant p53 and reactivates its function 22 brings hope for patients harboring TP53 gene mutations.
Given that approximately around 2/3 of all human cancers harbour TP53 gene mutations (https://p53.fr/), a development of a new approach to compensate for p53 loss, is of the outmost clinical relevance. Small molecules reactivating TAp73 are of a special interest. Few molecules directly or indirectly activating TAp73 in cancer cells have been described in literature. Small molecule Nutlin3, a potent inhibitor of p53/MDM2 interactions was found to activate p73 and induce p73-mediated apoptosis by disrupting p73/HDM2 association in cancer cells lacking p53 8 . Next, small molecule RETRA was described to specifically suppress mutant p53-bearing tumor cells in vitro and in mouse xenografts by disrupting mtp53/p73 complex 23 . The widely-used genotoxic drug cisplatin (CDDP) was also shown to induce TAp73mediated apoptosis in ovarian cancer cells irrespective of p53 status. Recent study showed that TAp73 sensitizes p53-null colon cancer cells to bortezomib and TAp73 was shown to compensate for p53-loss in induction of apoptosis after drug treatment 24 .
Our previous findings showed that protoporphyrin IX binds to p53 and activates p53dependent and independent cell death in colon cancer cells 12 . Consistently, PpIX was shown to induce cancer cell death in sarcoma cells 25 . In line with our data (Figure 1d Recently, detailed analysis of the oligomeric state of TAp73 alpha by Melino and Dötsch labs revealed a high structure homology between p53 and p73 tetramers 26 .
This shows that p73 can be pharmacologically restored in a way similar to p53. This is supported by our previous and current findings, which showed that PpIX binds to p73 and induces accumulation of TAp73 and its apoptotic targets in cancer cells in a fashion similar to p53. Using siRNA we determined that TAp73 is crucial for induction of apoptosis in cancer cells treated with PpIX. This supports the notion that pharmacologically restored TAp73 behaves similarly to activated wild-type p53 and that TAp73 can compensate for p53 loss in cancer cells lacking TP53 gene.
To gain better insight into the mechanism of activation of TAp73 in cancer cells by PpIX, we used a yeast-based reporter system previously developed to screen for activators of p53 15 Since mRNA levels of p73 were not elevated by PpIX we reasoned, that the increase on the protein level must be related to the prolonged stability of TAp73 in cancer cells. Chase experiments confirmed that PpIX stabilizes TAp73 on protein level. The stabilization was a consequence of disruption of interactions between TAp73 and E3 ubiquitin ligase, Itch in cancer cells.
Taken together, our data showed that PpIX, a metabolite of aminolevulinic acid, activates TAp73 by several mechanisms converging on activation of its transcriptional activity and protein stabilization leading to transactivation of pro-apoptotic PUMA and NOXA. Next, pharmacologically activated TAp73 compensates for p53 loss and induces apoptosis in cancer cells. Our findings, might in future lead to successful repurposing of porphyrins into clinical application to treat tumors with TP53 gene mutations.
Methods
All experiments including protocols were performed in accordance with the guidelines and regulations of Karolinska Institute and the University of Gdansk.
Cell culture and chemicals
The p53-deficient human colon cancer cells HCT 116 TP53 -/- 28 
Co-Immunoprecipitation and Western blotting
Statistical analysis
Yeast assay was performed in 3 independent experiments with 3 triplicates. P < 0.05 was considered statistically relevant. The statistical significance was assessed by a 
